Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NuPathe privately raises $28mm

Executive Summary

NuPathe Inc. (neurological drug delivery) has raised $28mm by selling 14mm units at $2 to first-time and returning institutional and individual investors led by Quaker Bioventures II and Safeguard Delaware. The company says the funds will sustain operations for one year, including gaining approval for its lead candidate, the transdermal migraine patch NP101 (sumatriptan), securing a partner, and pre-launch preparations.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Private Placement

Related Companies